Provided By GlobeNewswire
Last update: Jun 25, 2024
The pooled analysis included data from 4 international clinical trials spanning an array of hard-to-treat indications including skin, head & neck, and oral cavity.
NASDAQ:DRTS (5/30/2025, 8:00:01 PM)
2.985
-0.02 (-0.5%)
NASDAQ:DRTSW (5/30/2025, 8:00:01 PM)
0.21
-0.04 (-16%)
Find more stocks in the Stock Screener